Triamcinolone acetonide, sold under the brand name Kenalog among others, is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various join. It is a potent glucocorticoid receptor agonist with anti-inflammatory and immunomodulatory effects mediated through inhibition of phospholipase A2 activity, reduced leukocyte infiltration, and suppression of proinflammatory cytokine and chemokine expression. Chemically it is the 16,17-acetonide derivative of triamcinolone, characterized by low aqueous solubility, good chemical stability in neutral media, and suitability for suspension and semisolid formulations. Typical pharmaceutical control points include particle size distribution, crystalline form, single-peak purity by HPLC, and validated potency by reverse-phase HPLC with UV detection. Common dosage forms include topical creams and ointments, dental pastes for mucosal lesions, and sterile injectable suspensions for intra-articular or intralesional use.
Parent: Triamcinolone Acetonide
Parent: Triamcinolone Acetonide
Parent: Triamcinolone Acetonide
Parent: Triamcinolone Acetonide
Parent: Triamcinolone Acetonide
Typical industry specifications for triamcinolone acetonide APIs focus on assay and related substances determined by validated HPLC methods. Typical assay acceptance is approximately 98.0 to 102.0 percent of the labeled amount by potency assay. Reporting thresholds for individual impurities are commonly set at 0.05 to 0.10 percent, individual identified unspecified impurities are typically limited to not more than 0.2 percent, and the total of all impurities is commonly limited to not more than 1.0 percent. Known related compounds and process or degradation products include the parent alcohol triamcinolone (deacetonide), acetylated derivatives, C-16 epimers, minor oxidation products and hydrolysis products derived from the acetonide ring, and trace solvent- or reagent-related residues. Limits for genotoxic or mutagenic impurities follow standard ICH-driven approaches and are typically set at very low levels consistent with qualification thresholds. Specifications should always reference the manufacturer validated method, system suitability criteria, and stability-indicating data.
Triamcinolone acetonide is used to reduce inflammation and immune-mediated symptoms. Topically it treats inflammatory dermatoses such as eczema, psoriasis, contact dermatitis and steroid-responsive rashes. As a dental paste it relieves the discomfort of aphthous mouth ulcers. By injection into joints or soft tissues it is used for short-term management of inflammatory and degenerative joint conditions and localized inflammatory lesions.
It is formulated as creams, ointments, lotions, dental pastes, and sterile injectable suspensions. API and finished product control are commonly performed by reverse-phase HPLC with UV detection, supported by assays for water content, residual solvents, particle size, and microbiological purity where applicable. Stability-indicating methods are used to monitor degradation.
Quality assurance uses validated HPLC methods with reporting thresholds around 0.05 to 0.10 percent for impurities, individual impurity limits often set at 0.2 percent, and total impurity limits around 1.0 percent. Specific limits for known related substances such as deacetonide triamcinolone and oxidation or hydrolysis products are defined in the API specification and are supported by forced-degradation and stability studies.
